BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 20734877)

  • 1. [Retroperitoneal lymphadenectomy in disseminated non-seminoma germinogenic testicular tumors after chemotherapy in patients with elevated serum tumor markers].
    Matveev VB; Volkova MI; Cherniev VA; Figurin KM; Mitin AV
    Urologiia; 2010; (3):41-7. PubMed ID: 20734877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
    Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
    Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
    J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
    Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
    J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
    Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of advanced seminoma: retrospective study of 96 patients].
    Bompas E; Fléchon A; Biron P; Droz JP
    Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
    Ong TA; Winkler MH; Savage PM; Seckl MJ; Christmas TJ
    BJU Int; 2008 Jul; 102(2):198-202. PubMed ID: 18294302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
    Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
    J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome.
    Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
    Urol Clin North Am; 2007 May; 34(2):219-25; abstract ix-x. PubMed ID: 17484926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?
    Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R
    Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
    Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
    Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
    Onozawa M; Kawai K; Yamamoto T; Hinotsu S; Tsukamoto S; Hattori K; Miyanaga N; Shimazui T; Akaza H
    Int J Urol; 2004 Jul; 11(7):535-41. PubMed ID: 15242364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
    Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
    Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.